Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 14/20 | 0.51 |
| ▸ | GIPR | P48546 | 3/20 | 0.51 |
| ▸ | GLP1R | P43220 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091217 | 0.73 | SMN1; SMN2 (0.52) | GCGRGIPRGLP1RSMN1; SMN2ALDH1A1 | |
| SCHEMBL2663548 | 0.73 | GCGR (0.56) | GCGRGIPRGLP1R | |
| SCHEMBL4092102 | 0.73 | CYP1A2 (0.47) | GCGRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2663520 | 0.70 | GCGR (0.81) | GCGRGIPRGLP1R | |
| SCHEMBL9072677 | 0.70 | EGFR (0.62) | GCGRGLP1RALDH1A1 | |
| SCHEMBL2651195 | 0.70 | GCGR (0.75) | GCGRGIPRGLP1R | |
| SCHEMBL2665808 | 0.69 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL2662978 | 0.69 | GCGR (0.65) | GCGRGIPRGLP1R | |
| SCHEMBL9072717 | 0.69 | GCGR (0.73) | GCGRGIPRGLP1R | |
| SCHEMBL2652053 | 0.69 | GCGR (0.79) | GCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |